Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $22,860.00 in Stock

Posted by Marion Hillson on Jan 31st, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $11.43, for a total transaction of $22,860.00. Following the completion of the transaction, the president now directly owns 2,893,138 shares in the company, valued at approximately $33,068,567.34. This represents a 0.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Songjiang Ma also recently made the following trade(s):

On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total value of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.49, for a total value of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.85, for a total value of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.72, for a total value of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.
On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total transaction of $565.60.
On Friday, January 10th, Songjiang Ma sold 1,057 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $10,591.14.
On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total value of $9,560.56.
On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total value of $24,800.00.
On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total value of $25,000.00.

Gyre Therapeutics Stock Performance

Shares of Gyre Therapeutics stock traded up $0.01 on Friday, hitting $11.51. 41,862 shares of the company’s stock traded hands, compared to its average volume of 101,694. The firm’s 50-day moving average is $11.09 and its 200 day moving average is $12.56. Gyre Therapeutics, Inc. has a 52-week low of $8.26 and a 52-week high of $26.37.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. FMR LLC bought a new stake in shares of Gyre Therapeutics in the 3rd quarter worth about $47,000. Barclays PLC grew its stake in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Gyre Therapeutics in the second quarter valued at about $166,000. Advantage Alpha Capital Partners LP acquired a new stake in Gyre Therapeutics during the third quarter valued at approximately $334,000. Finally, State Street Corp lifted its holdings in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after buying an additional 8,412 shares during the last quarter. 23.99% of the stock is currently owned by institutional investors.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.